Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 5,156 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cervical Clear all
Completed Early Phase 1 Interventional Results available

Neoadjuvant Imiquimod Immunotherapy for Oral Cancer

NCT04883645
View directory record Official record
Conditions
Oral Squamous Cell Carcinoma
Interventions
Imiquimod 5% Cream
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck

NCT00402545
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Cetuximab, Docetaxel, Cisplatin, 5-Fluorouracil
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2009 · Synced Oct 25, 2026, 5:40 AM EDT
Not listed Phase 2 Interventional

Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer

NCT04018872
View directory record Official record
Conditions
Esophagus Adenocarcinoma, Esophagus Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Itraconazole
Drug
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 25, 2026, 5:40 AM EDT
Withdrawn Not applicable Interventional

Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease

NCT01616719
View directory record Official record
Conditions
Cervical Spondylosis, Cervical Radiculopathy, Cervical Degenerative Disc Disease
Interventions
DTRAX Graft
Device
Lead sponsor
Providence Medical Technology, Inc.
Industry
Eligibility
35 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 25, 2026, 5:40 AM EDT
Enrolling by invitation No phase listed Observational

Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion

NCT06000319
View directory record Official record
Conditions
Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Stenosis
Interventions
Natural Matrix Protein (NMP) Fibers, Lumbar interbody fusion, Cervical interbody fusion
Biological · Procedure
Lead sponsor
Induce Biologics USA Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jasper, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Phase 2 Interventional

Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia

NCT02706795
View directory record Official record
Conditions
Torticollis (Spasmodic)
Interventions
DaxibotulinumtoxinA
Biological
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
13
States / cities
Fountain Valley, California • Colorado Springs, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

NCT03189719
View directory record Official record
Conditions
Esophageal Neoplasms
Interventions
Pembrolizumab, Placebo, Cisplatin, 5-FU
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
12
States / cities
West Los Angeles, California • Chicago, Illinois • Westwood, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer

NCT00226239
View directory record Official record
Conditions
Cancer
Interventions
Docetaxel, Cisplatin, Cetuximab, Radiation Therapy
Drug · Procedure
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

NCT01598077
View directory record Official record
Conditions
HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma
Interventions
LJM716
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 25, 2026, 5:40 AM EDT
Recruiting Phase 2 Interventional

Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial

NCT07178301
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
Computed Tomography, Nasopharyngeal Laryngoscopy, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy
Procedure · Other · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
2
States / cities
Chicago, Illinois • Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Not yet recruiting Not applicable Interventional

Decision Aid Efficacy in Low Risk Thyroid Cancer

NCT07536412
View directory record Official record
Conditions
Differentiated Thyroid Cancer (DTC), Papillary Thyroid Microcarcinoma, Papillary Thyroid Carcinoma
Interventions
Decision Aid
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Phase 3 Interventional Results available

Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)

NCT00117572
View directory record Official record
Conditions
Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Nasal Cavity, Paranasal Sinus Neoplasms, Cancer of the Oral Cavity
Interventions
docetaxel, cisplatin, hydroxyurea, fluorouracil, chemotherapy, radiotherapy
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Miami, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 25, 2026, 5:40 AM EDT
Recruiting Phase 1Phase 2 Interventional

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

NCT06780111
View directory record Official record
Conditions
Esophageal Squamous Cell Carcinoma
Interventions
Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Sacituzumab tirumotecan, Rescue Medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Phase 1 Interventional Results available

Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)

NCT02626000
View directory record Official record
Conditions
Carcinoma of the Head and Neck
Interventions
Talimogene Laherparepvec, Pembrolizumab
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
Newark, Delaware • Chicago, Illinois • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)

NCT01183065
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Pralatrexate With Vitamin B12 and Folic Acid
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Not applicable Interventional

Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance

NCT02405000
View directory record Official record
Conditions
Oropharyngeal Cancer
Interventions
Intraoperative CT imaging
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 25, 2026, 5:40 AM EDT
Recruiting Phase 2 Interventional

Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery

NCT06959511
View directory record Official record
Conditions
Neoadjuvant Treatment, Thyroid Cancer
Interventions
Zanzalintinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

NCT02124707
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions
Cetuximab, Paclitaxel, Carboplatin
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Midlothian, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 25, 2026, 5:40 AM EDT
Completed No phase listed Observational

PET MRI as a Staging Tool for Head and Neck Cancer

NCT04750434
View directory record Official record
Conditions
Head Cancer, Neck Cancer
Interventions
Not listed
Lead sponsor
Hoag Memorial Hospital Presbyterian
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Phase 1 Interventional

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

NCT03022409
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Ceralasertib, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Phase 2 Interventional Results available

F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients

NCT00721799
View directory record Official record
Conditions
Mouth Neoplasms, Oropharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Neoplasms
Interventions
18F-Fluorothymidine PET scan
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Not applicable Interventional Results available

Single-arm Phase II Study of NDURE for Patients With HNC

NCT03821064
View directory record Official record
Conditions
Cancer of Head and Neck
Interventions
Patient Navigation
Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 25, 2026, 5:40 AM EDT
Recruiting Not applicable Interventional

Neuromodulation to Improve Respiratory Function in Cervical Spinal Cord Injury

NCT04883463
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Epidural stimulation
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 25, 2026, 5:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Manual Therapy and Augmented Exercise for Neck Pain

NCT01750736
View directory record Official record
Conditions
Neck Pain
Interventions
Augmented Exercise and Manual Therapy, General Exercise and Manual Therapy
Other
Lead sponsor
Des Moines University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Des Moines, Iowa • North Canton, Ohio • Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 25, 2026, 5:40 AM EDT